Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

27.25 -0.14 (-0.51%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Moderna, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
15 16 Next >
EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Authorization Of Moderna's Omicron BA.4-BA.5 Targeting Bivalent Covid-19 Vaccine In The European Union
Via ACCESSWIRE
EMA Committee for Medicinal Products for Human Use Issues Positive Opinion Recommending Authorization for the Use of Spikevax (mRNA-1273) in Children 6 Months - 5 Years in the European Union
Via ACCESSWIRE
90-Day Analysis Shows Moderna’s Omicron BA.1-Targeting Bivalent Vaccine, mRNA-1273.214, Demonstrates Superior Antibody Response as Fourth Booster Compared to Spikevax Prototype Booster
Via ACCESSWIRE
Merck Nears Breakout Point After October Surprise Good News
Dow component Merck is within 2% of an all-time high after rallying 7.30% in the past month. It got a boost from news about two new treatments. 
Via MarketBeat
Topics Stocks
Exposures US Equities
Moderna Announces Update to 2022 Supply Agreement with Gavi that Secures Access to Updated Variant-Specific COVID-19 Vaccines for Low-and-Middle Income Countries
Via ACCESSWIRE
Moderna Receives FDA Authorization for Emergency Use of Omicron-Targeting Bivalent COVID-19 Booster Vaccine for Children and Adolescents 6 to 17 Years of Age
Via ACCESSWIRE
Moderna Creates New Executive Committee Role Ahead of New Product Launches
Via ACCESSWIRE
Indonesia's Bio Farma ready to produce IndoVac Covid-19 vaccines
Via JCN Newswire
Exposures COVID-19
Moderna to Report Third Quarter 2022 Financial Results on Thursday, November 3, 2022
Via ACCESSWIRE
Merck and Moderna Announce Exercise of Option by Merck for Joint Development and Commercialization of Investigational Personalized Cancer Vaccine
Via ACCESSWIRE
Moderna exercises option to license proprietary targeting technology from Autolus
From Autolus Therapeutics plc
Via GlobeNewswire
Is Pfizer Stock Still Worth Buying After the Pandemic?
Pharmaceutical giant Pfizer (NYSE: PFE) is literally synonymous with COVID-19 vaccines, and as a result, Pfizer stock continues to beat expectations. 
Via MarketBeat
Exposures COVID-19
Moderna Reviews Clinical Trial Programs Across Portfolio at 2022 R&D Day
Via ACCESSWIRE
Health Canada Authorizes Moderna's Omicron-Targeting Bivalent COVID-19 Booster Vaccine
Via ACCESSWIRE
Moderna to Host R&D Day on Thursday, September 8, 2022
Via ACCESSWIRE
Swissmedic Authorizes Moderna’s Omicron-Targeting Bivalent Booster Candidate, MRNA-1273.214
Via ACCESSWIRE
European Medicines Agency Accepts Moderna's Conditional Marketing Authorization Filing for its Omicron BA.4/BA.5 Targeting Bivalent COVID-19 Vaccine
Via ACCESSWIRE
Novavax Remains a Risk-On Stock in a Risk-Off Market
NVAX is a risk-on stock at a time investors are turning to risk-off assets. This article looks to see if Novavax still presents an opportunity for investors 
Via MarketBeat
Topics Earnings
Exposures Financial
Ministry Of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.214
Via ACCESSWIRE
Indonesia's Bio Farma ready to produce 'IndoVac' Covid-19 vaccines
Via ACN Newswire
Exposures COVID-19
Indonesian pharmaceutical Bio Farma ready to produce IndoVac Covid-19 vaccines
Via ACN Newswire
Exposures COVID-19
Moderna to Supply 12 Million Doses of Omicron-Containing Bivalent COVID-19 Booster Vaccines to the Government of Canada
Via ACCESSWIRE
Moderna to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
Via ACCESSWIRE
EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for the Use of Moderna's Omicron-Targeting Bivalent Booster in the European Union
Via ACCESSWIRE
Moderna Receives FDA Authorization for Emergency Use of Omicron-Targeting Bivalent COVID-19 Booster Vaccine for Adults 18 Years and Older
Via ACCESSWIRE
Therapeutic Goods Administration Provisionally Approves Moderna’s Omicron-Containing Bivalent Booster Candidate, MRNA-1273.214, For Australia
Via ACCESSWIRE
Moderna Sues Pfizer and BioNTech for Infringing Patents Central to Moderna's Innovative mRNA Technology Platform
Via ACCESSWIRE
Moderna Completes Application To U.S. Food And Drug Administration For Emergency Use Authorization Of Omicron-Targeting Bivalent Covid-19 Booster Vaccine, mRNA-1273.222
Via ACCESSWIRE
James Mock Joins Moderna as Chief Financial Officer
Via ACCESSWIRE
Medicines and Healthcare Products Regulatory Agency (MHRA) Authorizes Moderna's Omicron-Containing Bivalent Booster in the UK
Via ACCESSWIRE
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.